Organogenesis HoldingsORGO
About: Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced wound care, surgical and sports medicine markets. Its product category includes Advanced Wound Care and Surgical and Sports Medicine. It has single operating segment which has regenerative medicine. The company generates maximum revenue from Advanced Wound Care products. Some of its products include PuraPly Antimicrobial, Affinity, NuShield, Apligraf, Dermagraft and others.
Employees: 862
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
0% more funds holding in top 10
Funds holding in top 10: 1 [Q2] → 1 (+0) [Q3]
3% less repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 40
3% less funds holding
Funds holding: 115 [Q2] → 111 (-4) [Q3]
8.27% less ownership
Funds ownership: 56.17% [Q2] → 47.9% (-8.27%) [Q3]
13% less capital invested
Capital invested by funds: $209M [Q2] → $182M (-$26.9M) [Q3]
22% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 18
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $66K
Research analyst outlook
We haven’t received any recent analyst ratings for ORGO.
Financial journalist opinion
Based on 6 articles about ORGO published over the past 30 days